Target- |
MechanismImmunostimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
The purpose of this study is to test safety and anti-tumor activity of BT062 in combination with lenalidomide and dexamethasone to define the best doses for treating patients with relapsed and refractory multiple myeloma.
A Phase I/IIa Multi-Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), Safety and Efficacy of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
This Phase I/IIa clinical study is to test safety and anti-tumor activity of BT062 to define the best dose in treating patients with relapsed or refractory multiple myeloma with multiple doses of BT062.
100 Clinical Results associated with BPC Plasma, Inc.
0 Patents (Medical) associated with BPC Plasma, Inc.
01 Jan 2012·Results in Immunology
Effective virus inactivation and removal by steps of Biotest Pharmaceuticals IGIV production process
Article
Author: Dougherty, Christopher J ; Kretschmar, Michael ; Dichtelmüller, Herbert O ; Sananes, Frank ; Flechsig, Eckhard
The virus validation of three steps of Biotest Pharmaceuticals IGIV production process is described here. The steps validated are precipitation and removal of fraction III of the cold ethanol fractionation process, solvent/detergent treatment and 35 nm virus filtration. Virus validation was performed considering combined worst case conditions. By these validated steps sufficient virus inactivation/removal is achieved, resulting in a virus safe product.
01 Jan 1989·Beitrage zur Infusionstherapie = Contributions to infusion therapy
[Virus safety of labile plasma products from the German viewpoint].
Review
Author: Stephan, W
Unstable plasma derivatives are sterilized in Germany according to three methods. Combined treatment with beta-propiolactone + UV irradiation: in use at Biotest since 1968; Pasteurisation in sulution, 10 h at 60 degrees C in the presence of a maltose-glycin stabilizer; in use at Behring Werke since 1980; Treatment with solvent + detergent (tri-n-butyl phosphate + Tween 80 (sodium cholate]: in use at DRK Hagen and Biotest since 1987/88. The safety of unstable plasma derivatives sterilized according to these methods has been shown in studies in chimpanzees as well as in clinical studies.
Contributions to infusion therapy
Virus safety of labile plasma products from the German viewpoint
Author: Stephan W
Unstable plasma derivatives are sterilized in Germany according to three methods. Combined treatment with beta-propiolactone + UV irradiation: in use at Biotest since 1968; Pasteurisation in sulution, 10 h at 60 degrees C in the presence of a maltose-glycin stabilizer; in use at Behring Werke since 1980; Treatment with solvent + detergent (tri-n-butyl phosphate + Tween 80 (sodium cholate]: in use at DRK Hagen and Biotest since 1987/88. The safety of unstable plasma derivatives sterilized according to these methods has been shown in studies in chimpanzees as well as in clinical studies.
100 Deals associated with BPC Plasma, Inc.
100 Translational Medicine associated with BPC Plasma, Inc.